The use of antiplatelet agents in acute cardiac care

Critical Care Clinics

Volumn 17, Issue 2, 2001, Pages 365-377

  Calvin, James E ^a   Klein, Lloyd W ^b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; ROXIFIBAN; SIBRAFIBAN; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

ANTICOAGULANT THERAPY; HEART INFARCTION; INTENSIVE CARE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0034956922     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70172-X     Document Type: Article

References (44)

1. Acute coronary syndromes
2. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
4. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial
5. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases
6. Clopidogrel versus ticlopidine after intracoronary stent placement
7. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
8. Clinicopathological correlates of acute ischemic heart disease syndromes
9. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
10. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
11. Experience with aspirin (acetysalicylic acid) in the non-specific prophylaxis of coronary thrombosis
12. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content
13. Thrombosis as a factor in the pathogenesis of coronary disease syndromes
14. Prehospital abciximab administration in the ADMIRAL study
15. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
16. Platelet glycoprotein IIa/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
17. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes
18. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor
19. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
20. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary thrombosis-II
21. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS- 2
22. Favorable results with immediate coronary intervention after low dose t-PA and eptifibatide for acute MI: Results from the INTRO-AMI trial
23. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
24. A clinical trial comparing three antithromboticdrug regimens after coronary-artery stenting
25. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina
26. Molecular bases of the acute coronary syndromes
27. Aspirin, the ageless remedy?
28. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
29. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
30. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina
31. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
32. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
33. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
34. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
35. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
36. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
37. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
38. Stenting and IIb/IIIa receptor blockade in acute myocardial infarction: An introduction to the CADILLAC trial
39. Accelerated dose eptifibatide in non-emergency coronary stenting: Preliminary results of the ESPRIT trial
40. Aspirin, heparin, or both to treat acute unstable angina
41. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
42. Differential dose effect of aspirin in primary prevention of myocardial infarction
43. Thrombolysis for acute myocardial infarction